Yoga-based, Movement Therapy Device as Noninvasive Glymphatic Clearance Augmentation in Alzheimer's Disease.
NCT ID: NCT06989242
Last Updated: 2025-07-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
60 participants
INTERVENTIONAL
2025-07-01
2026-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pilot Trial for Adults With Acquired Brain Injury
NCT05793827
Testing the Efficacy of Social Robot-led Yoga
NCT05476614
Lifestyle for the BRAin Health - Time Restricted Eating and Mindfulness
NCT07042087
Physical Exercise And Cognitive Engagement Outcomes for Mild Neurocognitive Disorder
NCT03095170
Movement Intervention for Memory Enhancement
NCT03475316
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The current trial builds on recent findings that highlight the effectiveness of mind-body interventions, such as yoga and deep abdominal breathing, in promoting healthy aging and slowing cognitive decline. Research suggests that yoga and body-mind practices can improve well-being and reduce biological markers of aging in both healthy older adults and those at risk for dementia. Yogic breathing and body movements may enhance cerebrospinal fluid (CSF) flow as an important component of the glymphatic function. The trial employs physiological measurements, including fNIRS and wearable sensors, to investigate the mechanisms and clinical benefits of yoga-based interventions for AD.
The primary objective is to assess the safety, tolerability, feasibility of a 4-week Fluere™ therapy protocol for stage 3 and 4 AD patients.
The secondary objectives focus on clinical effectiveness related to:
1. Body posture improvement
2. Changes in HRV (reflecting the stress level and quality of sleep)
Although the duration of the study is short, and the study is not powered to detect changes in biomarkers or clinical efficacy, secondary endpoints will be analyzed to assess trends in improvement from baseline.
Additional secondary outcomes will focus on biomarker proxies of glymphatic clearance:
1. Impact on digital biomarkers (neuro-fluid dynamics (hemodynamics, CSF) and redox state of cytochrome-c-oxidase activity using fNIRS)
2. Effect on plasma biomarkers associated with neurodegeneration, inflammation and neural plasticity - GFAP, NfL and S100B and BDNF
3. Cognitive (spatial memory) and functional outcomes
4. Sleep patterns and quality through wearable devices and questionnaires
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention Arm - Device-Guided Movement and Breathing
Participants in this arm will receive a yoga-based intervention delivered through a powered therapeutic device that guides rhythmic breathing and spinal movement. The intervention is designed to mimic traditional yoga poses such as Marjariasana (cat-cow) and is conducted over multiple sessions. The study aims to assess feasibility, safety, and preliminary effects on cognitive function, physiological measures (e.g., fNIRS, HRV, posture), and fluid biomarkers in individuals with Alzheimer's disease (stages 3 and 4).
Yoga-Based Therapeutic Device (incorporating guided breathing and movement)
The Fluere™ Therapeutic Device is a computer-guided, electro-mechanical system designed to simulate yoga-inspired spinal movement and rhythmic breathing. Resembling a dental chair, the device dynamically adjusts spinal curvature to replicate motion patterns associated with deep abdominal breathing, similar to Kundalini or Qi Gong breathwork. The device operates automatically, with optional manual adjustments by the researcher.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Yoga-Based Therapeutic Device (incorporating guided breathing and movement)
The Fluere™ Therapeutic Device is a computer-guided, electro-mechanical system designed to simulate yoga-inspired spinal movement and rhythmic breathing. Resembling a dental chair, the device dynamically adjusts spinal curvature to replicate motion patterns associated with deep abdominal breathing, similar to Kundalini or Qi Gong breathwork. The device operates automatically, with optional manual adjustments by the researcher.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current diagnostic criteria for stage 3 AD patients (AD-MCI)
* Current diagnostic criteria for stage 4 AD patients (mAD)
* Able to provide consent to be in the study
* Willing and able to participate in study activities
* Able to lay supine for 30-45 minutes
* Able to walk 20 meters
* Willing to not perform additional mind-body practices during the duration of the study
* Able to use a wearable electronic device (Smart watch)
Exclusion Criteria
* Regular use of muscle relaxants or anti-anxiety drugs
* Any muscle or skeletal issues that would make it difficult to lie still in the supine position for the 1-hour physical therapy
* Craniospinal disorders, e.g., Chiari Malformation.
* Spinal injuries, clinically relevant disc herniation, spinal stenosis, spondylolisthesis in the sacral, lumbar, thoracic, or cervical spine, spinal bifida, Recent Spinal Surgery
* Severe osteoporosis with a risk of fracture
* History of neurological disorders such as stroke (during the last year before study start), mild brain injury within past 6 months, multiple sclerosis, presence of intracranial hemorrhage, hydrocephalus, meningitis, encephalitis, brain tumor (except of asymptomatic meningioma GI)
* Serious sleep disorders - narcolepsy
* Major or uncontrolled psychiatric illness or major depression.
* Any condition requiring the use of medication that acts on the brain such as stimulants, sedatives (hypnotics and benzodiazepines), antipsychotics, and anti-anxiety medications, (we will include patients with stable antidepressant treatment and being on mild anti-seizure medication due to polyneuropathy)
* Active infection or uncontrolled significant systemic illnesses
* Asthma, chronic obstructive pulmonary disease
* Recent hearth attack, Implantable defibrillator, poorly controlled blood pressure cardiac arrhythmia, unstable angina pectoris, or symptomatic congestive heart failure
* People at risk of blood clots or deep vein thrombosis (DVT) might want to avoid prolonged sitting in the chair
* Obesity over 135 kg (300lb)
* Smoking more than 5 cigarettes a day or drinking more than 1 alcoholic beverage a day
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Oulu
OTHER
CIATRIX, INC.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Patrik Simko, MA. PhD.
Role: STUDY_DIRECTOR
Masaryk University, The International Clinical Research Center of St. Anne's University Hospital in Brno (FNUSA-ICRC), CIATRIX Inc.
Katerina Sheardova, MD. PhD.
Role: PRINCIPAL_INVESTIGATOR
The International Clinical Research Center of St. Anne's University Hospital in Brno (FNUSA-ICRC)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Neuro Health Centrum S.R.O
Brno, , Czechia
Neuropsychiatrie s.r.o., Terronska 580/19
Prague, , Czechia
AuraMedica s.r.o., Neurologická ambulancia, OMNIA BUSINESS CENTER, Tomášikova 19081/28C
Bratislava, Slovakia, Slovakia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RG-CZSK-PH2
Identifier Type: OTHER
Identifier Source: secondary_id
RG-CZSK-PH2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.